HIGHLIGHTS
- who: HSV et al. from the Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom, Virtuu Biologics/Sorrento have published the article: Inconsistencies in Modeling the Ef cacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability, in the Journal: (JOURNAL)
- how: The authors investigated the clinical relevance of this finding using pleural effusion samples from a phase I/IIa trial of intrapleural administration of HSV1716 which reported good tolerability among patients as well as an antitumor immune_response (Danson et_al 2020). The data are in accord with this theory yet rather . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.